Heckman, PhD, co-leader of the Cancer Prevention and Control Program at Rutgers Cancer Institute and an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, is corresponding author and shares some insight
The Food and Drug Administration (FDA) approved the distribution of PT 141 under Vyleesi and Bremelanotides brand name in 2019 for treating hypoactive sexual desire disorder
It is important to discuss potential side effects with your healthcare provider and report any adverse reactions you experience
If the GLP-1 neurons in the hindbrain are activated by physiological or pharmacological methods, or if the central GLP-1 receptors are activated, Rinaman said, this suppresses motivated behaviors such as food intake, drug self-administration, operant responding for drugs, and exploratory behaviors (Maniscalco and Rinaman, 2018)